|Publication number||US20050137687 A1|
|Application number||US 10/746,240|
|Publication date||Jun 23, 2005|
|Filing date||Dec 23, 2003|
|Priority date||Dec 23, 2003|
|Publication number||10746240, 746240, US 2005/0137687 A1, US 2005/137687 A1, US 20050137687 A1, US 20050137687A1, US 2005137687 A1, US 2005137687A1, US-A1-20050137687, US-A1-2005137687, US2005/0137687A1, US2005/137687A1, US20050137687 A1, US20050137687A1, US2005137687 A1, US2005137687A1|
|Inventors||Amr Salahieh, Brian Brandt, Dwight Morejohn, Ulrich Haug, Jean-Pierre Dueri, Hans Valencia, Robert Geshlider, Jeff Krolik|
|Original Assignee||Sadra Medical|
|Export Citation||BiBTeX, EndNote, RefMan|
|Patent Citations (99), Referenced by (60), Classifications (19), Legal Events (2)|
|External Links: USPTO, USPTO Assignment, Espacenet|
The present invention relates to methods and apparatus for endovascularly replacing a heart valve. More particularly, the present invention relates to methods and apparatus for endovascularly replacing a heart valve with a replacement valve using an expandable and retrievable anchor.
Heart valve surgery is used to repair or replace diseased heart valves. Valve surgery is an open-heart procedure conducted under general anesthesia. An incision is made through the patient's sternum (sternotomy), and the patient's heart is stopped while blood flow is rerouted through a heart-lung bypass machine.
Valve replacement may be indicated when there is a narrowing of the native heart valve, commonly referred to as stenosis, or when the native valve leaks or regurgitates. When replacing the valve, the native valve is excised and replaced with either a biologic or a mechanical valve. Mechanical valves require lifelong anticoagulant medication to prevent blood clot formation, and clicking of the valve often may be heard through the chest. Biologic tissue valves typically do not require such medication. Tissue valves may be obtained from cadavers or may be porcine or bovine, and are commonly attached to synthetic rings that are secured to the patient's heart.
Valve replacement surgery is a highly invasive operation with significant concomitant risk. Risks include bleeding, infection, stroke, heart attack, arrhythmia, renal failure, adverse reactions to the anesthesia medications, as well as sudden death. 2-5% of patients die during surgery.
Post-surgery, patients temporarily may be confused due to emboli and other factors associated with the heart-lung machine. The first 2-3 days following surgery are spent in an intensive care unit where heart functions can be closely monitored. The average hospital stay is between 1 to 2 weeks, with several more weeks to months required for complete recovery.
In recent years, advancements in minimally invasive surgery and interventional cardiology have encouraged some investigators to pursue percutaneous replacement of the aortic heart valve. Percutaneous Valve Technologies (“PVT”) of Fort Lee, N.J., has developed a balloon-expandable stent integrated with a bioprosthetic valve. The stent/valve device is deployed across the native diseased valve to permanently hold the valve open, thereby alleviating a need to excise the native valve and to position the bioprosthetic valve in place of the native valve. PVT's device is designed for delivery in a cardiac catheterization laboratory under local anesthesia using fluoroscopic guidance, thereby avoiding general anesthesia and open-heart surgery. The device was first implanted in a patient in April of 2002.
PVT's device suffers from several drawbacks. Deployment of PVT's stent is not reversible, and the stent is not retrievable. This is a critical drawback because improper positioning too far up towards the aorta risks blocking the coronary ostia of the patient. Furthermore, a misplaced stent/valve in the other direction (away from the aorta, closer to the ventricle) will impinge on the mitral apparatus and eventually wear through the leaflet as the leaflet continuously rubs against the edge of the stent/valve.
Another drawback of the PVT device is its relatively large cross-sectional delivery profile. The PVT system's stent/valve combination is mounted onto a delivery balloon, making retrograde delivery through the aorta challenging. An antegrade transseptal approach may therefore be needed, requiring puncture of the septum and routing through the mitral valve, which significantly increases complexity and risk of the procedure. Very few cardiologists are currently trained in performing a transseptal puncture, which is a challenging procedure by itself.
Other prior art replacement heart valves use self-expanding stents as anchors. In the endovascular aortic valve replacement procedure, accurate placement of aortic valves relative to coronary ostia and the mitral valve is critical. Standard self-expanding systems have very poor accuracy in deployment, however. Often the proximal end of the stent is not released from the delivery system until accurate placement is verified by fluoroscopy, and the stent typically jumps once released. It is therefore often impossible to know where the ends of the stent will be with respect to the native valve, the coronary ostia and the mitral valve.
Also, visualization of the way the new valve is functioning prior to final deployment is very desirable. Visualization prior to final and irreversible deployment cannot be done with standard self-expanding systems, however, and the replacement valve is often not fully functional before final deployment.
Another drawback of prior art self-expanding replacement heart valve systems is their lack of radial strength. In order for self-expanding systems to be easily delivered through a delivery sheath, the metal needs to flex and bend inside the delivery catheter without being plastically deformed. In arterial stents, this is not a challenge, and there are many commercial arterial stent systems that apply adequate radial force against the vessel wall and yet can collapse to a small enough of a diameter to fit inside a delivery catheter without plastically deforming. However when the stent has a valve fastened inside it, as is the case in aortic valve replacement, the anchoring of the stent to vessel walls is significantly challenged during diastole. The force to hold back arterial pressure and prevent blood from going back inside the ventricle during diastole will be directly transferred to the stent/vessel wall interface. Therefore the amount of radial force required to keep the self expanding stent/valve in contact with the vessel wall and not sliding will be much higher than in stents that do not have valves inside of them. Moreover, a self-expanding stent without sufficient radial force will end up dilating and contracting with each heartbeat, thereby distorting the valve, affecting its function and possibly migrating and dislodging completely. Simply increasing strut thickness of the self-expanding stent is not a practical solution as it runs the risk of larger profile and/or plastic deformation of the self-expanding stent.
U.S. patent application Serial No. 2002/0151970 to Garrison et al. describes a two-piece device for replacement of the aortic valve that is adapted for delivery through a patient's aorta. A stent is endovascularly placed across the native valve, then a replacement valve is positioned within the lumen of the stent. By separating the stent and the valve during delivery, a profile of the device's delivery system may be sufficiently reduced to allow aortic delivery without requiring a transseptal approach. Both the stent and a frame of the replacement valve may be balloon-expandable or self-expanding.
While providing for an aortic approach, devices described in the Garrison patent application suffer from several drawbacks. First, the stent portion of the device is delivered across the native valve as a single piece in a single step, which precludes dynamic repositioning of the stent during delivery. Stent foreshortening or migration during expansion may lead to improper alignment.
Additionally, Garrison's stent simply crushes the native valve leaflets against the heart wall and does not engage the leaflets in a manner that would provide positive registration of the device relative to the native position of the valve. This increases an immediate risk of blocking the coronary ostia, as well as a longer-term risk of migration of the device post-implantation. Furtherstill, the stent comprises openings or gaps in which the replacement valve is seated post-delivery. Tissue may protrude through these gaps, thereby increasing a risk of improper seating of the valve within the stent.
In view of drawbacks associated with previously known techniques for endovascularly replacing a heart valve, it would be desirable to provide methods and apparatus that overcome those drawbacks.
The invention provides apparatus and methods for endovascularly replacing a patient's heart valve. One aspect of the invention provides an apparatus including: an expandable anchor with a lip region and a skirt region; and a replacement valve, wherein the lip region and skirt region are configured for percutaneous expansion (e.g., independent expansion or concurrent expansion) to engage leaflets of the heart valve. The lip and/or skirt regions may be adapted to preclude migration of the apparatus post-deployment and expansion. Expansion of the anchor and replacement valve may be by balloon-expansion, self-expansion, and combinations thereof. A locking element may be provided to maintain expansion.
The invention also includes a delivery system that facilitates deployment and expansion of the apparatus to endovascularly replace the heart valve and, in some embodiments, retrieve the apparatus.
Another aspect of the invention provides a method for endovascularly replacing a patient's heart valve. In some embodiments the method includes the steps of: endovascularly delivering apparatus having an anchor having lip and skirt regions, and a replacement valve coupled to the anchor, to a vicinity of the heart valve in a collapsed delivery configuration; and expanding the apparatus such that leaflets of the heart valve are captured between the lip and skirt regions of the anchor. The expanding step of the method may include the step of dynamically repositioning the apparatus relative to the heart valve prior to capturing the leaflets. The expanding step may also include the steps of expanding either the lip region or the skirt region, positively engaging the heart valve with the expanded lip or skirt region, and then expanding the unexpanded region. The apparatus may be retrieved, repositioned and redeployed, and the apparatus may be locked in its expanded configuration.
All publications and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.
The novel features of the invention are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings of which:
FIGS. 1A-B are elevational views of a replacement heart valve and anchor according to one embodiment of the invention.
FIGS. 2A-B are sectional views of the anchor and valve of
FIGS. 3A-B show delivery and deployment of a replacement heart valve and anchor, such as the anchor and valve of
FIGS. 4A-E also show delivery and deployment of a replacement heart valve and anchor, such as the anchor and valve of
FIGS. 5A-F show the use of a replacement heart valve and anchor to replace an aortic valve.
FIGS. 6A-F show the use of a replacement heart valve and anchor with a positive registration feature to replace an aortic valve.
FIGS. 8A-C show another embodiment of a replacement heart valve and anchor according to the invention.
FIGS. 9A-H show delivery and deployment of the replacement heart valve and anchor of
FIGS. 11A-C show alternative locks for use with replacement heart valves and anchors of this invention.
FIGS. 12A-C show a vessel wall engaging lock for use with replacement heart valves and anchors of this invention.
FIGS. 15A-E show alternative arrangements of seals on a replacement heart valve and anchor.
FIGS. 16A-C show alternative seal designs for use with replacement heart valves and anchors.
FIGS. 35A-H show yet another embodiment of a replacement heart valve, anchor and deployment system according to this invention.
FIGS. 36A-E show more detail of the anchor of the embodiment shown in FIGS. 35A-H.
FIGS. 37A-B show other embodiments of the replacement heart valve and anchor of the invention.
FIGS. 38A-C illustrate a method for endovascularly replacing a patient's diseased heart valve.
FIGS. 39A-B show an anchor for use in a two-piece replacement heart valve and anchor embodiment of the invention.
FIGS. 40A-B show a replacement heart valve for use in a two-piece replacement heart valve and anchor embodiment of the invention.
FIGS. 41A-D show a method of coupling the anchor of
FIGS. 45A-I illustrate a method of delivering and deploying a two-piece replacement heart valve and anchor.
FIGS. 46A-B shows another embodiment of a two-piece replacement heart valve and anchor according to this invention.
While preferred embodiments of the present invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein may be employed in practicing the invention. It is intended that the following claims define the scope of the invention and that methods and structures within the scope of these claims and their equivalents be covered thereby.
With reference now to
Anchor 30 has a lip region 32, a skirt region 34 and a body region 36. First, second and third posts 38 a, 38 b and 38 c, respectively, are coupled to skirt region 34 and extend within lumen 31 of anchor 30. Posts 38 preferably are spaced 120° apart from one another about the circumference of anchor 30.
Anchor 30 preferably is fabricated by using self-expanding patterns (laser cut or chemically milled), braids and materials, such as a stainless steel, nickel-titanium (“Nitinol”) or cobalt chromium but alternatively may be fabricated using balloon-expandable patterns where the anchor is designed to plastically deform to it's final shape by means of balloon expansion. Replacement valve 20 is preferably from biologic tissues, e.g. porcine valve leaflets or bovine or equine pericardium tissues, alternatively it can be made from tissue engineered materials (such as extracellular matrix material from Small Intestinal Submucosa (SIS)) but alternatively may be prosthetic from an elastomeric polymer or silicone, Nitinol or stainless steel mesh or pattern (sputtered, chemically milled or laser cut). The leaflet may also be made of a composite of the elastomeric or silicone materials and metal alloys or other fibers such Kevlar or carbon. Annular base 22 of replacement valve 20 preferably is coupled to skirt region 34 of anchor 30, while commissures 24 of replacement valve leaflets 26 are coupled to posts 38.
Anchor 30 may be actuated using external non-hydraulic or non-pneumatic force to actively foreshorten in order to increase its radial strength. As shown below, the proximal and distal end regions of anchor 30 may be actuated independently. The anchor and valve may be placed and expanded in order to visualize their location with respect to the native valve and other anatomical features and to visualize operation of the valve. The anchor and valve may thereafter be repositioned and even retrieved into the delivery sheath or catheter. The apparatus may be delivered to the vicinity of the patient's aortic valve in a retrograde approach in a catheter having a diameter no more than 23 french, preferably no more than 21 french, more preferably no more than 19 french, or more preferably no more than 17 french. Upon deployment the anchor and replacement valve capture the native valve leaflets and positively lock to maintain configuration and position.
A deployment tool is used to actuate, reposition, lock and/or retrieve anchor 30. In order to avoid delivery of anchor 30 on a balloon for balloon expansion, a non-hydraulic or non-pneumatic anchor actuator is used. In this embodiment, the actuator is a deployment tool that includes distal region control wires 50, control rods or tubes 60 and proximal region control wires 62. Locks 40 include posts or arms 38 preferably with male interlocking elements 44 extending from skirt region 34 and mating female interlocking elements 42 in lip region 32. Male interlocking elements 44 have eyelets 45. Control wires 50 pass from a delivery system for apparatus 10 through female interlocking elements 42, through eyelets 45 of male interlocking elements 44, and back through female interlocking elements 42, such that a double strand of wire 50 passes through each female interlocking element 42 for manipulation by a medical practitioner external to the patient to actuate and control the anchor by changing the anchor's shape. Control wires 50 may comprise, for example, strands of suture.
Tubes 60 are reversibly coupled to apparatus 10 and may be used in conjunction with wires 50 to actuate anchor 30, e.g., to foreshorten and lock apparatus 10 in the fully deployed configuration. Tubes 60 also facilitate repositioning and retrieval of apparatus 10, as described hereinafter. For example, anchor 30 may be foreshortened and radially expanded by applying a distally directed force on tubes 60 while proximally retracting wires 50. As seen in
Deployment of apparatus 10 is fully reversible until lock 40 has been locked via mating of male interlocking elements 44 with female interlocking elements 42. Deployment is then completed by decoupling tubes 60 from lip section 32 of anchor 30 by retracting one end of each wire 62 relative to the other end of the wire, and by retracting one end of each wire 50 relative to the other end of the wire until each wire has been removed from eyelet 45 of its corresponding male interlocking element 44.
As best seen in
With reference now to
During foreshortening, tubes 60 push against lip region 32 of anchor 30, while wires 50 pull on posts 38 of the anchor. Wires 62 may be retracted along with wires 50 to enhance the distally-directed pushing force applied by tubes 60 to lip region 32. Continued retraction of wires 50 relative to tubes 60 would lock locks 40 and fully deploy apparatus 10 with replacement valve 20 properly seated within anchor 30, as in
Deployment of apparatus 10 is fully reversible until locks 40 have been actuated. For example, just prior to locking the position of the anchor and valve and the operation of the valve may be observed under fluoroscopy. If the position needs to be changed, by alternately relaxing and reapplying the proximally directed forces exerted by control wires 50 and/or control wires 62 and the distally directed forces exerted by tubes 60, expansion and contraction of the lip and skirt regions of anchor 30 may be independently controlled so that the anchor and valve can be moved to, e.g., avoid blocking the coronary ostia or impinging on the mitral valve. Apparatus 10 may also be completely retrieved within lumen 112 of sheath 110 by simultaneously proximally retracting wires 50 and tubes 60/wires 62 relative to sheath 110. Apparatus 10 then may be removed from the patient or repositioned for subsequent redeployment.
Referring now to
Apparatus 10 is deployed from lumen 112 of sheath 110, for example, under fluoroscopic guidance, such that anchor 30 of apparatus 10 dynamically self-expands to a partially deployed configuration, as in
Once properly aligned, wires 50 are retracted relative to tubes 60 to impose foreshortening upon anchor 30 and expand apparatus 10 to the fully deployed configuration, as in
As seen in
With reference now to
Delivery system 100′ comprises leaflet engagement element 120, which preferably self-expands along with anchor 30. Engagement element 120 is disposed between tubes 60 of delivery system 100′ and lip region 32 of anchor 30. Element 120 releasably engages the anchor. As seen in
Alternatively, foreshortening may be imposed upon anchor 30 while element 120 is disposed proximal of the leaflets, as in
With reference to
Referring now to
As an alternative delivery method, anchor 30′ may be partially deployed via partial expansion of inflatable member 130. The inflatable member would then be advanced within replacement valve 20 prior to inflation of inflatable member 130 and full deployment of apparatus 10″. Inflation pressures used will range from about 3 to 6 atm, or more preferably from about 4 to 5 atm, though higher and lower atm pressures may also be used (e.g., greater than 3 atm, more preferably greater than 4 atm, more preferably greater than 5 atm, or more preferably greater than 6 atm). Advantageously, separation of inflatable member 130 from replacement valve 20, until partial deployment of apparatus 10″ at a treatment site, is expected to reduce a delivery profile of the apparatus, as compared to previously known apparatus. This profile reduction may facilitate retrograde delivery and deployment of apparatus 10″, even when anchor 30′ is balloon-expandable.
Although anchor 30′ has illustratively been described as fabricated from balloon-expandable materials, it should be understood that anchor 30′ alternatively may be fabricated from self-expanding materials whose expansion optionally may be balloon-assisted. In such a configuration, anchor 30′ would expand to a partially deployed configuration upon removal of outer sheath 110. If required, inflatable member 130 then would be advanced within replacement valve 20 prior to inflation. Inflatable member 130 would assist full deployment of apparatus 10″, for example, when the radial force required to overcome resistance from impinging tissue were too great to be overcome simply by manipulation of wires 50 and tubes 60. Advantageously, optional placement of inflatable member 130 within replacement valve 20, only after dynamic self-expansion of apparatus 10″ to the partially deployed configuration at a treatment site, is expected to reduce a delivery profile of the apparatus, as compared to previously known apparatus. This reduction may facilitate retrograde delivery and deployment of apparatus 10″.
With reference to
The angioplasty balloon catheter or inflatable member 130 then is advanced within the replacement valve, as in
As will be apparent to those of skill in the art, the order of imposed foreshortening and balloon expansion described in
Referring now to
Advantageously, providing multiple arrowheads 46 along posts 38 yields a ratchet that facilitates in-vivo determination of a degree of foreshortening imposed upon apparatus of the present invention. Furthermore, optionally constraining appendages 48 of arrowheads 46 via eyelets 49 prevents actuation of lock 40″ (and thus deployment of apparatus of the present invention) even after male element 44′ has been advanced through female element 42. Only after a medical practitioner has removed the wire constraining appendages 48 is lock 40″ fully engaged and deployment no longer reversible.
Lock 40′″ of
With reference to
With reference now to
With reference to
With reference to
FIGS. 35A-H show another embodiment of a replacement heart valve apparatus in accordance with the present invention. Apparatus 450 comprises replacement valve 460 (see
As seen in
As seen in
As will be apparent to those of skill in the art, lip region 472 optionally may be expanded prior to expansion of skirt region 474. As yet another alternative, lip region 472 and skirt region 474 optionally may be expanded simultaneously, in parallel, in a step-wise fashion or sequentially. Advantageously, delivery of apparatus 450 is fully reversible until lip region 472 or skirt region 474 has been locked in the expanded configuration.
With reference now to FIGS. 36A-E, individual cells of anchor 470 of apparatus 450 are described to detail deployment and expansion of the apparatus. In
Body region 476 a comprises male interlocking element 482 of lip lock 480, while body region 476 b comprises female interlocking element 484 of lip lock 480. Male element 482 comprises eyelet 483. Wire 424 b passes from female interlocking element 484 through eyelet 483 and back through female interlocking element 484, such that there is a double strand of wire 424 b that passes through lumen 422 of catheter 420 for manipulation by a medical practitioner external to the patient. Body region 476 b further comprises male interlocking element 492 of skirt lock 490, while body region 476 c comprises female interlocking element 494 of the skirt lock. Wire 424 a passes from female interlocking element 494 through eyelet 493 of male interlocking element 492, and back through female interlocking element 494. Lip lock 480 is configured to maintain expansion of lip region 472, while skirt lock 490 is configured to maintain expansion of skirt region 474.
With reference to FIGS. 37A-B, isometric views, partially in section, further illustrate apparatus 450 in the fully deployed and expanded configuration.
Referring to FIGS. 38A-C, in conjunction with
Once properly positioned, wires 424 a are retracted to expand skirt region 474 of anchor 470 within left ventricle LV. Skirt region 474 is locked in the expanded configuration via skirt lock 490, as previously described with respect to
Wires 424 b are then actuated external to the patient in order to expand lip region 472, as previously described in
As seen in
With reference to
When replacing a patient's aortic valve, apparatus 510 preferably may be delivered through the patient's aorta without requiring a transseptal approach, thereby reducing patient trauma, complications and recovery time. Furthermore, apparatus 510 enables dynamic repositioning of anchor piece 550 during delivery and facilitates positive registration of apparatus 510 relative to the native position of the patient's valve, thereby reducing a risk of device migration and reducing a risk of blocking or impeding flow to the patient's coronary ostia. Furthermore, the expanded deployed configuration of apparatus 510, as seen in
As seen in
Groove section 570 of anchor piece 550 is adapted to engage an expandable frame portion, described hereinbelow, of valve piece 600 to couple anchor piece 550 to valve piece 600. As compared to previously known apparatus, groove section 570 comprises additional material and reduced openings or gaps G, which is expected to reduce tissue protrusion through the gaps upon deployment, thereby facilitating proper seating of the valve within the anchor. Groove section 570 optionally may be covered or coated with biocompatible film B (see
Finally, skirt section 580 of anchor piece 550 maintains proper positioning of composite anchor/valve apparatus 510 post-deployment by precluding proximal migration. When replacing a patient's aortic valve, skirt section 580 is deployed within the patient's left ventricle. As with lip section 560 and groove section 570, skirt section 580 optionally may be covered or coated with biocompatible film B (see
The basic anchor cell structure seen in
If balloon expandable, anchor piece 550 would be formed from an appropriate material, such as stainless steel, and then crimped onto a balloon delivery catheter in a collapsed delivery configuration. If self-expanding and formed from a shape-memory material, such as a nickel-titanium alloy (“Nitinol”), the anchor piece would be heat-set such that it could be constrained within a sheath in the collapsed delivery configuration, and then would dynamically self-expand to the expanded deployed configuration upon removal of the sheath. Likewise, if anchor piece 550 were formed from a wire mesh or braid, such as a spring steel braid, the anchor would be constrained within a sheath in the delivery configuration and dynamically expanded to the deployed configuration upon removal of the sheath.
Referring again to
Anchor piece 550 and valve piece 600 of apparatus 510 preferably are spaced apart and releasably coupled to a single delivery catheter while disposed in their reduced delivery configurations. Spacing the anchor and valve apart reduces a delivery profile of the device, thereby enabling delivery through a patient's aorta without requiring a transseptal approach. With reference to
Delivery system 700 comprises delivery catheter 710 having inner tube 720, middle distal tube 730, and outer tube 740. Inner tube 720 comprises lumen 722 adapted for advancement over a standard guide wire, per se known. Middle distal tube 730 is coaxially disposed about a distal region of inner tube 720 and is coupled to a distal end 724 of the inner tube, thereby forming proximally-oriented annular bore 732 between inner tube 720 and middle tube 730 at a distal region of delivery catheter 710. Outer tube 740 is coaxially disposed about inner tube 720 and extends from a proximal region of the inner tube to a position at least partially coaxially overlapping middle distal tube 730. Outer tube 740 preferably comprises distal step 742, wherein lumen 743 of outer tube 740 is of increased diameter. Distal step 742 may overlap middle distal tube 730 and may also facilitate deployment of valve piece 600, as described hereinbelow with respect to
Proximally-oriented annular bore 732 between inner tube 720 and middle distal tube 730 is adapted to receive skirt section 580 and groove section 570 of anchor piece 550 in the reduced delivery configuration. Annular space 744 formed at the overlap between middle distal tube 730 and outer tube 740 is adapted to receive lip section 560 of anchor piece 550 in the reduced delivery configuration. More proximal annular space 746 between inner tube 720 and outer tube 740 may be adapted to receive replacement valve 610 and expandable frame 620 of valve piece 600 in the reduced delivery configuration.
Inner tube 720 optionally may comprise retainer elements 726 a and 726 b to reduce migration of valve piece 600. Retainer elements 726 preferably are fabricated from a radiopaque material, such as platinum-iridium or gold, to facilitate deployment of valve piece 600, as well as coupling of the valve piece to anchor piece 550. Additional or alternative radiopaque elements may be disposed at other locations about delivery system 700 or apparatus 510, for example, in the vicinity of anchor piece 550.
With reference now to
Delivery catheter 710′ is substantially equivalent to catheter 710 described hereinabove, except that catheter 710′ does not comprise retainer elements 726, and annular space 746 does not receive valve piece 600. Rather, valve piece 600 is received within catheter 760 in the collapsed delivery configuration. Catheter 760 comprises inner tube 770 and outer tube 780. Inner tube 770 comprises lumen 772 for advancement of catheter 760 over a guide wire. The inner tube optionally may also comprise retainer elements 774 a and 774 b, e.g. radiopaque retainer elements 774, to reduce migration of valve piece 600. Outer tube 780 is coaxially disposed about inner tuber 770 and preferably comprises distal step 782 to facilitate deployment and coupling of valve piece 600 to anchor piece 550, as described hereinbelow. Valve piece 600 may be received in annular space 776 between inner tube 770 and outer tube 780, and more preferably may be received within annular space 776 between retainer elements 774.
Referring now to
With reference now to
Aortic valve AV comprises native valve leaflets L attached to valve annulus An. Coronary ostia O are disposed just proximal of diseased aortic valve AV. Coronary ostia O connect the patient's coronary arteries to aorta A and are the conduits through which the patient's heart muscle receives oxygenated blood. As such, it is critical that the ostia remain unobstructed post-deployment of apparatus 510.
Lip section 560 may be dynamically repositioned until it properly engages the valve leaflets, thereby ensuring proper positioning of anchor piece 550 relative to the native coronary ostia 0, as well as the valve annulus An, prior to deployment of groove section 570 and skirt section 580. Such multi-step deployment of anchor piece 550 enables positive registration and dynamic repositioning of the anchor piece. This is in contrast to previously known percutaneous valve replacement apparatus.
As seen in
With anchor piece 550 deployed and native aortic valve AV displaced, valve piece 600 may be deployed and coupled to the anchor piece to achieve percutaneous aortic valve replacement. Outer tube 740 is further proximally retracted relative to inner tube 720 such that valve piece 600 is partially deployed from annular space 746 between inner tube 720 and outer tube 740, as seen in
Subsequent re-advancement of outer tube 740 relative to inner tube 720 causes distal step 742 to distally advance valve piece 600 within anchor piece 550 until tips 622 of expandable frame 620 engage groove section 570 of anchor piece 550, as seen in
Hoop 624 friction locks within groove section 570 of anchor piece 550, thereby coupling the anchor piece to the valve piece and forming composite two-piece apparatus 510, which provides a percutaneous valve replacement. As seen in
Referring now to
When anchor piece 550′ is self-expanding and collapsed in the delivery configuration, guideposts 653 may be deployed with skirt section 580′, in which case guideposts 653 would rotate upward with respect to anchor piece 550′ into the deployed configuration of
Sleeves 655 of second portion 654 of alignment/locking mechanism 650 comprise lumens 656 sized for coaxial disposal of sleeves 655 about guideposts 653 of first portion 652. Upon deployment, sleeves 655 may friction lock to guideposts 653 to ensure proper radial and longitudinal alignment of anchor piece 550′ with valve piece 600′, as well as to provide a secondary lock of the anchor piece to the valve piece. The secondary lock enhances the primary friction lock formed by groove section 570′ of the anchor piece with hoop 624′ of expandable frame 620′ of the valve piece.
To facilitate coupling of the anchor piece to the valve piece, suture or thread may pass from optional eyelets 651 a of guideposts 653 through lumens 656 of sleeves 655 to a proximal end of the delivery catheter (see
Referring now to
With reference now to
Female guides 672 are translatable about male posts 670, but are constrained by flared ends 671 of the male posts. In this manner, anchor piece 550′″ and valve piece 600′″ remain coupled and in radial alignment with one another at all times—including delivery—but may be longitudinally separated from one another during delivery. This facilitates percutaneous delivery without requiring a transseptal approach, while mitigating a risk of inadvertent deployment of the anchor and valve pieces in an uncoupled configuration. Additional alignment/locking mechanisms will be apparent in view of the mechanisms described with respect to
Prior to implantation of one of the replacement valves described above, it may be desirable to perform a valvoplasty on the diseased valve by inserting a balloon into the valve and expanding it using saline mixed with a contrast agent. In addition to preparing the valve site for implant, fluoroscopic viewing of the valvoplasty will help determine the appropriate size of replacement valve implant to use.
|Cited Patent||Filing date||Publication date||Applicant||Title|
|US4106126 *||Aug 11, 1977||Aug 15, 1978||Traenkle William J||Within-the-shoe sock having removable retaining device|
|US4106129 *||Aug 26, 1977||Aug 15, 1978||American Hospital Supply Corporation||Supported bioprosthetic heart valve with compliant orifice ring|
|US4501030 *||Aug 17, 1981||Feb 26, 1985||American Hospital Supply Corporation||Method of leaflet attachment for prosthetic heart valves|
|US4796629 *||Jun 3, 1987||Jan 10, 1989||Joseph Grayzel||Stiffened dilation balloon catheter device|
|US4986830 *||Sep 22, 1989||Jan 22, 1991||Schneider (U.S.A.) Inc.||Valvuloplasty catheter with balloon which remains stable during inflation|
|US5209741 *||Jul 8, 1991||May 11, 1993||Endomedix Corporation||Surgical access device having variable post-insertion cross-sectional geometry|
|US5332402 *||May 12, 1992||Jul 26, 1994||Teitelbaum George P||Percutaneously-inserted cardiac valve|
|US5411552 *||Jun 14, 1994||May 2, 1995||Andersen; Henning R.||Valve prothesis for implantation in the body and a catheter for implanting such valve prothesis|
|US5425762 *||Jun 1, 1993||Jun 20, 1995||Muller; Guy-Henri||Prosthetic implants and process for obtaining the same|
|US5443495 *||Sep 17, 1993||Aug 22, 1995||Scimed Lifesystems Inc.||Polymerization angioplasty balloon implant device|
|US5545133 *||Sep 16, 1994||Aug 13, 1996||Scimed Life Systems, Inc.||Balloon catheter with improved pressure source|
|US5554185 *||Jul 18, 1994||Sep 10, 1996||Block; Peter C.||Inflatable prosthetic cardiovascular valve for percutaneous transluminal implantation of same|
|US5667523 *||Apr 28, 1995||Sep 16, 1997||Impra, Inc.||Dual supported intraluminal graft|
|US5855597 *||May 7, 1997||Jan 5, 1999||Iowa-India Investments Co. Limited||Stent valve and stent graft for percutaneous surgery|
|US5855601 *||Jun 21, 1996||Jan 5, 1999||The Trustees Of Columbia University In The City Of New York||Artificial heart valve and method and device for implanting the same|
|US5887266 *||Feb 7, 1996||Mar 23, 1999||Nokia Mobile Phones Limited||Method for using applications in a mobile station, a mobile station and a system for effecting payments|
|US5910154 *||Feb 12, 1998||Jun 8, 1999||Embol-X, Inc.||Percutaneous catheter and guidewire having filter and medical device deployment|
|US5911734 *||May 8, 1997||Jun 15, 1999||Embol-X, Inc.||Percutaneous catheter and guidewire having filter and medical device deployment capabilities|
|US5925063 *||Sep 26, 1997||Jul 20, 1999||Khosravi; Farhad||Coiled sheet valve, filter or occlusive device and methods of use|
|US5954766 *||Sep 16, 1997||Sep 21, 1999||Zadno-Azizi; Gholam-Reza||Body fluid flow control device|
|US5957949 *||May 1, 1997||Sep 28, 1999||World Medical Manufacturing Corp.||Percutaneous placement valve stent|
|US6027520 *||Apr 5, 1999||Feb 22, 2000||Embol-X, Inc.||Percutaneous catheter and guidewire having filter and medical device deployment capabilities|
|US6042598 *||Apr 5, 1999||Mar 28, 2000||Embol-X Inc.||Method of protecting a patient from embolization during cardiac surgery|
|US6042607 *||Feb 21, 1997||Mar 28, 2000||Cardiovascular Technologies Llc||Means and method of replacing a heart valve in a minimally invasive manner|
|US6051104 *||Aug 13, 1997||Apr 18, 2000||Fort James Corporation||Soft single-ply tissue having very low sideness|
|US6168579 *||Aug 4, 1999||Jan 2, 2001||Scimed Life Systems, Inc.||Filter flush system and methods of use|
|US6168614 *||Feb 20, 1998||Jan 2, 2001||Heartport, Inc.||Valve prosthesis for implantation in the body|
|US6171327 *||Feb 24, 1999||Jan 9, 2001||Scimed Life Systems, Inc.||Intravascular filter and method|
|US6179859 *||Jul 16, 1999||Jan 30, 2001||Baff Llc||Emboli filtration system and methods of use|
|US6258120 *||Dec 23, 1997||Jul 10, 2001||Embol-X, Inc.||Implantable cerebral protection device and methods of use|
|US6270513 *||Dec 3, 1999||Aug 7, 2001||Embol-X, Inc.||Methods of protecting a patient from embolization during surgery|
|US6336934 *||Nov 9, 1998||Jan 8, 2002||Salviac Limited||Embolic protection device|
|US6338735 *||Mar 15, 1996||Jan 15, 2002||John H. Stevens||Methods for removing embolic material in blood flowing through a patient's ascending aorta|
|US6348063 *||Jan 18, 2000||Feb 19, 2002||Mindguard Ltd.||Implantable stroke treating device|
|US6371970 *||Dec 23, 1999||Apr 16, 2002||Incept Llc||Vascular filter having articulation region and methods of use in the ascending aorta|
|US6371983 *||Oct 3, 2000||Apr 16, 2002||Ernest Lane||Bioprosthetic heart valve|
|US6440164 *||Oct 21, 1999||Aug 27, 2002||Scimed Life Systems, Inc.||Implantable prosthetic valve|
|US6503272 *||Mar 21, 2001||Jan 7, 2003||Cordis Corporation||Stent-based venous valves|
|US6508833 *||Mar 12, 2001||Jan 21, 2003||Cook Incorporated||Multiple-sided intraluminal medical device|
|US6527800 *||Jun 8, 2001||Mar 4, 2003||Rex Medical, L.P.||Vascular device and method for valve leaflet apposition|
|US6537297 *||Jun 26, 2001||Mar 25, 2003||Embol-X, Inc.||Methods of protecting a patient from embolization during surgery|
|US6540768 *||Feb 9, 2000||Apr 1, 2003||Cordis Corporation||Vascular filter system|
|US6562058 *||Mar 2, 2001||May 13, 2003||Jacques Seguin||Intravascular filter system|
|US6592546 *||Jan 30, 1998||Jul 15, 2003||Edwards Lifesciences Corp.||Aortic occluder with associated filter and methods of use during cardiac surgery|
|US6592614 *||Dec 1, 2000||Jul 15, 2003||Medtronic Ave, Inc.||Cuffed endoluminal prosthesis|
|US6673089 *||Aug 11, 2000||Jan 6, 2004||Mindguard Ltd.||Implantable stroke treating device|
|US6676698 *||Dec 5, 2001||Jan 13, 2004||Rex Medicol, L.P.||Vascular device with valve for approximating vessel wall|
|US6682559 *||Jan 29, 2001||Jan 27, 2004||3F Therapeutics, Inc.||Prosthetic heart valve|
|US6685739 *||Jul 9, 2002||Feb 3, 2004||Scimed Life Systems, Inc.||Implantable prosthetic valve|
|US6689144 *||Feb 8, 2002||Feb 10, 2004||Scimed Life Systems, Inc.||Rapid exchange catheter and methods for delivery of vaso-occlusive devices|
|US6689164 *||Oct 10, 2000||Feb 10, 2004||Jacques Seguin||Annuloplasty device for use in minimally invasive procedure|
|US6692512 *||Jun 25, 2001||Feb 17, 2004||Edwards Lifesciences Corporation||Percutaneous filtration catheter for valve repair surgery and methods of use|
|US6695864 *||Jul 3, 2001||Feb 24, 2004||Cardeon Corporation||Method and apparatus for cerebral embolic protection|
|US6695865 *||Apr 29, 2002||Feb 24, 2004||Advanced Bio Prosthetic Surfaces, Ltd.||Embolic protection device|
|US6773454 *||Jan 2, 2001||Aug 10, 2004||Michael H. Wholey||Tapered endovascular stent graft and method of treating abdominal aortic aneurysms and distal iliac aneurysms|
|US6890340 *||Nov 29, 2001||May 10, 2005||Medtronic Vascular, Inc.||Apparatus for temporary intraluminal protection|
|US6905743 *||Oct 25, 2000||Jun 14, 2005||Boston Scientific Scimed, Inc.||Dimensionally stable balloons|
|US6911036 *||Mar 15, 2002||Jun 28, 2005||Medtronic Vascular, Inc.||Guidewire apparatus for temporary distal embolic protection|
|US6936067 *||May 17, 2001||Aug 30, 2005||St. Jude Medical Inc.||Prosthetic heart valve with slit stent|
|US6984242 *||Dec 20, 2002||Jan 10, 2006||Gore Enterprise Holdings, Inc.||Implantable medical device assembly|
|US20010025196 *||Dec 21, 2000||Sep 27, 2001||Chinn Joseph Andrew||Prosthetic heart valve with surface modification|
|US20020010489 *||Jul 24, 2001||Jan 24, 2002||Jeffrey Grayzel||Stiffened balloon catheter for dilatation and stenting|
|US20020052651 *||Jan 29, 2001||May 2, 2002||Keith Myers||Prosthetic heart valve|
|US20020095173 *||Jan 18, 2002||Jul 18, 2002||Microvena Corporation||Method and device for filtering body fluid|
|US20030014104 *||May 2, 2002||Jan 16, 2003||Alain Cribier||Value prosthesis for implantation in body channels|
|US20030023303 *||Apr 11, 2002||Jan 30, 2003||Palmaz Julio C.||Valvular prostheses having metal or pseudometallic construction and methods of manufacture|
|US20030036791 *||Aug 2, 2002||Feb 20, 2003||Bonhoeffer Philipp||Implant implantation unit and procedure for implanting the unit|
|US20030060844 *||Jul 19, 2002||Mar 27, 2003||Thomas Borillo||Vascular filter system|
|US20030149476 *||Feb 28, 2001||Aug 7, 2003||Christoph Damm||Anchoring system for implantable heart valve prostheses|
|US20030149478 *||Feb 28, 2001||Aug 7, 2003||Hans-Reiner Figulla||Device for fastening and anchoring cardiac valve prostheses|
|US20030176884 *||Mar 12, 2002||Sep 18, 2003||Marwane Berrada||Everted filter device|
|US20040034411 *||Aug 16, 2002||Feb 19, 2004||Quijano Rodolfo C.||Percutaneously delivered heart valve and delivery means thereof|
|US20040049262 *||Jun 9, 2003||Mar 11, 2004||Obermiller Joseph F.||Stent valves and uses of same|
|US20040073198 *||Mar 26, 2003||Apr 15, 2004||Salviac Limited||Embolic protection device|
|US20040082967 *||Oct 25, 2002||Apr 29, 2004||Scimed Life Systems, Inc.||Multiple membrane embolic protection filter|
|US20040093016 *||Nov 3, 2003||May 13, 2004||Scimed Life Systems, Inc.||Percutaneous catheter and guidewire for filtering during ablation of myocardial or vascular tissue|
|US20040116951 *||Nov 12, 2003||Jun 17, 2004||Rosengart Todd K.||Apparatus and method for cutting a heart valve|
|US20040122468 *||Dec 1, 2003||Jun 24, 2004||Mindguard Ltd.||Braided intraluminal device for stroke prevention|
|US20040138694 *||Jan 15, 2003||Jul 15, 2004||Scimed Life Systems, Inc.||Intravascular filtering membrane and method of making an embolic protection filter device|
|US20040158277 *||Dec 16, 2003||Aug 12, 2004||Scimed Life Systems, Inc.||Embolic protection filter delivery sheath|
|US20040167565 *||Feb 24, 2003||Aug 26, 2004||Scimed Life Systems, Inc.||Embolic protection filtering device that can be adapted to be advanced over a guidewire|
|US20040186563 *||Mar 18, 2003||Sep 23, 2004||Lobbi Mario M.||Minimally-invasive heart valve with cusp positioners|
|US20050075662 *||May 14, 2004||Apr 7, 2005||Wesley Pedersen||Valvuloplasty catheter|
|US20050085841 *||Sep 2, 2004||Apr 21, 2005||Eversull Christian S.||Expandable sheath for delivering instruments and agents into a body lumen and methods for use|
|US20050085842 *||Sep 2, 2004||Apr 21, 2005||Eversull Christian S.||Expandable guide sheath and apparatus with distal protection and methods for use|
|US20050085843 *||Sep 17, 2004||Apr 21, 2005||Nmt Medical, Inc.||Quick release knot attachment system|
|US20050085890 *||Oct 12, 2004||Apr 21, 2005||Cook Incorporated||Prosthesis deployment system retention device|
|US20050090846 *||May 27, 2004||Apr 28, 2005||Wesley Pedersen||Valvuloplasty devices and methods|
|US20050096692 *||Sep 9, 2004||May 5, 2005||Linder Richard J.||Methods, systems, and devices for providing embolic protection and removing embolic material|
|US20050096734 *||Oct 31, 2003||May 5, 2005||Majercak David C.||Implantable valvular prosthesis|
|US20050096735 *||Oct 31, 2003||May 5, 2005||Hikmat Hojeibane||Implantable valvular prosthesis|
|US20050096736 *||Apr 30, 2004||May 5, 2005||Osse Francisco J.||Percutaneous heart valve devices|
|US20050096738 *||Oct 6, 2003||May 5, 2005||Cali Douglas S.||Minimally invasive valve replacement system|
|US20050100580 *||Oct 14, 2004||May 12, 2005||Cook Incorporated||Hydrophilic coated medical device|
|US20050113910 *||Jul 10, 2004||May 26, 2005||David Paniagua||Percutaneously implantable replacement heart valve device and method of making same|
|US20050137695 *||Aug 3, 2004||Jun 23, 2005||Sadra Medical||Replacement valve and anchor|
|US20050165352 *||Jan 23, 2004||Jul 28, 2005||Scimed Life Systems, Inc.||Stent delivery catheter|
|US20050165477 *||Mar 18, 2005||Jul 28, 2005||3F Therapeutics, Inc., A California Corporation||Percutaneously deliverable heart valve|
|US20050197695 *||Feb 25, 2005||Sep 8, 2005||Sorin Biomedica Cardio S.R.L.||Minimally-invasive cardiac-valve prosthesis|
|Citing Patent||Filing date||Publication date||Applicant||Title|
|US7534261||Oct 2, 2006||May 19, 2009||Edwards Lifesciences Corporation||Sutureless heart valve attachment|
|US7655037 *||Apr 17, 2008||Feb 2, 2010||Cordis Corporation||Combination barb restraint and stent attachment deployment mechanism|
|US7658762||Jan 4, 2008||Feb 9, 2010||Direct Flow Medical, Inc.||Nonstented temporary valve for cardiovascular therapy|
|US7704222||Aug 30, 2004||Apr 27, 2010||Jenavalve Technology, Inc.||Methods and conduits for flowing blood from a heart chamber to a blood vessel|
|US7708775||May 24, 2006||May 4, 2010||Edwards Lifesciences Corporation||Methods for rapid deployment of prosthetic heart valves|
|US7712606||Feb 2, 2006||May 11, 2010||Sadra Medical, Inc.||Two-part package for medical implant|
|US7736327||May 9, 2008||Jun 15, 2010||Jenavalve Technology, Inc.||Methods and conduits for flowing blood from a heart chamber to a blood vessel|
|US7749266||Feb 27, 2006||Jul 6, 2010||Aortx, Inc.||Methods and devices for delivery of prosthetic heart valves and other prosthetics|
|US7785341||Aug 31, 2010||Aortx, Inc.||Prosthetic heart valves, scaffolding structures, and systems and methods for implantation of same|
|US7819915||Dec 19, 2003||Oct 26, 2010||Edwards Lifesciences Corporation||Heart valve holders and handling clips therefor|
|US7824443||Feb 2, 2006||Nov 2, 2010||Sadra Medical, Inc.||Medical implant delivery and deployment tool|
|US7857845||Feb 10, 2006||Dec 28, 2010||Sorin Biomedica Cardio S.R.L.||Cardiac-valve prosthesis|
|US7896913||Sep 5, 2006||Mar 1, 2011||Jenavalve Technology, Inc.||Anchoring system for implantable heart valve prostheses|
|US7896915||Apr 13, 2007||Mar 1, 2011||Jenavalve Technology, Inc.||Medical device for treating a heart valve insufficiency|
|US7914575||Oct 2, 2009||Mar 29, 2011||Jenavalve Technology, Inc.||Medical device for treating a heart valve insufficiency|
|US7935144||Oct 19, 2007||May 3, 2011||Direct Flow Medical, Inc.||Profile reduction of valve implant|
|US7951197||Apr 6, 2009||May 31, 2011||Medtronic, Inc.||Two-piece prosthetic valves with snap-in connection and methods for use|
|US7988724 *||Feb 14, 2007||Aug 2, 2011||Sadra Medical, Inc.||Systems and methods for delivering a medical implant|
|US8048153||Nov 1, 2011||Sadra Medical, Inc.||Low profile heart valve and delivery system|
|US8092521||Jan 10, 2012||Jenavalve Technology, Inc.||Device for the implantation and fixation of prosthetic valves|
|US8142497||May 11, 2009||Mar 27, 2012||Edwards Lifesciences Corporation||Sutureless heart valve attachment|
|US8377118 *||May 5, 2005||Feb 19, 2013||Direct Flow Medical, Inc.||Unstented heart valve with formed in place support structure|
|US8414635||Apr 9, 2013||Idev Technologies, Inc.||Plain woven stents|
|US8449625||May 28, 2013||Edwards Lifesciences Corporation||Methods of measuring heart valve annuluses for valve replacement|
|US8540768||Dec 30, 2011||Sep 24, 2013||Sorin Group Italia S.R.L.||Cardiac valve prosthesis|
|US8579962||Dec 20, 2005||Nov 12, 2013||Sadra Medical, Inc.||Methods and apparatus for performing valvuloplasty|
|US8617236 *||Nov 2, 2011||Dec 31, 2013||Sadra Medical, Inc.||Medical devices and delivery systems for delivering medical devices|
|US8623076||Sep 22, 2011||Jan 7, 2014||Sadra Medical, Inc.||Low profile heart valve and delivery system|
|US8696742||Oct 10, 2012||Apr 15, 2014||Edwards Lifesciences Corporation||Unitary quick-connect prosthetic heart valve deployment methods|
|US8771346 *||Jul 25, 2011||Jul 8, 2014||Medtronic Ventor Technologies Ltd.||Valve prosthetic fixation techniques using sandwiching|
|US8795356||Feb 21, 2014||Aug 5, 2014||Cardiaq Valve Technologies, Inc.||Vascular implant|
|US8840664||Jun 14, 2012||Sep 23, 2014||Edwards Lifesciences Corporation||Heart valve prosthesis anchoring device and methods|
|US8851286||Nov 14, 2012||Oct 7, 2014||Boston Scientific Scimed Inc.||Dual sterilization containment vessel|
|US8858620 *||Jun 10, 2011||Oct 14, 2014||Sadra Medical Inc.||Methods and apparatus for endovascularly replacing a heart valve|
|US8870916||Jul 5, 2007||Oct 28, 2014||USGI Medical, Inc||Low profile tissue anchors, tissue anchor systems, and methods for their delivery and use|
|US8870948||Jan 31, 2014||Oct 28, 2014||Cephea Valve Technologies, Inc.||System and method for cardiac valve repair and replacement|
|US8876880||Jul 13, 2012||Nov 4, 2014||Board Of Regents, The University Of Texas System||Plain woven stents|
|US8911455||Dec 21, 2012||Dec 16, 2014||Cardiaq Valve Technologies, Inc.||Delivery system for vascular implant|
|US8920492||Aug 21, 2013||Dec 30, 2014||Sorin Group Italia S.R.L.||Cardiac valve prosthesis|
|US8974516||Dec 17, 2013||Mar 10, 2015||Board Of Regents, The University Of Texas System||Plain woven stents|
|US9044318||Feb 26, 2008||Jun 2, 2015||Jenavalve Technology Gmbh||Stent for the positioning and anchoring of a valvular prosthesis|
|US9044320||Sep 6, 2013||Jun 2, 2015||Jenavalve Technology Gmbh||Device for the implantation and fixation of prosthetic valves|
|US9056008||Nov 9, 2011||Jun 16, 2015||Sorin Group Italia S.R.L.||Instrument and method for in situ development of cardiac valve prostheses|
|US9078747||Nov 13, 2012||Jul 14, 2015||Edwards Lifesciences Corporation||Anchoring device for replacing or repairing a heart valve|
|US20050033220 *||Aug 30, 2004||Feb 10, 2005||Percardia, Inc.||Left ventricular conduit with blood vessel graft|
|US20060020327 *||May 5, 2005||Jan 26, 2006||Lashinski Randall T||Nonstented heart valves with formed in situ support|
|US20060020333 *||May 5, 2005||Jan 26, 2006||Lashinski Randall T||Method of in situ formation of translumenally deployable heart valve support|
|US20060020334 *||May 5, 2005||Jan 26, 2006||Lashinski Randall T||Methods of cardiac valve replacement using nonstented prosthetic valve|
|US20110288634 *||Nov 24, 2011||Medtronic Vascular, Inc.||Valve Prosthetic Fixation Techniques Using Sandwiching|
|US20120016469 *||Jan 19, 2012||Sadra Medical Inc.||Methods and Apparatus for Endovascularly Replacing a Heart Valve|
|US20120046740 *||Nov 2, 2011||Feb 23, 2012||Sadra Medical, Inc.||Medical devices and delivery systems for delivering medical devices|
|US20120053685 *||Aug 25, 2011||Mar 1, 2012||Biotronik Ag||Medical valve implant for implantation in an animal body and/or human body|
|US20120179239 *||Jan 9, 2012||Jul 12, 2012||Cardiaq Valve Technologies, Inc.||Vascular prosthesis connecting stent|
|US20120277855 *||Nov 1, 2012||Direct Flow Medical, Inc.||Percutaneous heart valve with inflatable support|
|US20130013057 *||Jan 10, 2013||Sadra Medical, Inc.||Medical implant deployment tool|
|US20130041458 *||Feb 14, 2013||Direct Flow Medical, Inc.||Method of in situ formation of translumenally deployable heart valve support|
|US20130096664 *||Feb 16, 2011||Apr 18, 2013||Transcatheter Technologies Gmbh||Medical Implant Maintaining Gaps upon Crimping, Method and Delivery Device|
|US20130138203 *||Jan 22, 2013||May 30, 2013||Cardiaq Valve Technologies, Inc.||Prosthesis having a plurality of distal and proximal prongs|
|WO2013169748A1||May 7, 2013||Nov 14, 2013||Boston Scientific Scimed, Inc.||Reduced profile valve with locking elements|
|WO2013191892A2||Jun 4, 2013||Dec 27, 2013||Boston Scientific Scimed, Inc.||Valvuloplasty device|
|U.S. Classification||623/2.11, 623/2.18, 623/1.36, 623/2.38|
|International Classification||A61F2/24, A61F2/06, A61F2/90|
|Cooperative Classification||A61F2/2433, A61F2/2439, A61F2/2436, A61F2250/006, A61F2230/005, A61F2002/9528, A61F2/2418, A61F2230/0054, A61F2220/0016, A61F2230/0078|
|European Classification||A61F2/24H6, A61F2/24D6|
|Jun 7, 2004||AS||Assignment|
Owner name: SADRA MEDICAL INC., CALIFORNIA
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SALAHIEH, AMR;BRANDT, BRIAN D.;MOREJOHN, DWIGHT P.;AND OTHERS;REEL/FRAME:014703/0867;SIGNING DATES FROM 20040301 TO 20040414
Owner name: SADRA MEDICAL INC., CALIFORNIA
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SALAHIEH, AMR;BRANDT, BRIAN D.;MOREJOHN, DWIGHT P.;AND OTHERS;REEL/FRAME:015447/0530;SIGNING DATES FROM 20040301 TO 20040414
|Jul 2, 2015||AS||Assignment|
Owner name: BOSTON SCIENTIFIC SCIMED, INC., MINNESOTA
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SADRA MEDICAL, INC.;REEL/FRAME:036049/0194
Effective date: 20150701